Here are four tings to know.
1. The drugmaker will eliminate about 3,500 positions globally, which will generate roughly $500 million in annual savings.
2. Most of the job cuts will come from a voluntary early-retirement program Eli Lilly is offering U.S. employees.
3. The drugmaker will also close a drug plant in Iowa, along with its research and development offices in New Jersey and China.
4. The layoffs follow a challenging year for Eli Lilly, which has encountered several major development setbacks for its experimental rheumatoid arthritis drug baricitinib and its Alzheimer’s treatment solanezumab.
More articles on supply chain:
Novo Nordisk settles diabetes drug lawsuit for $58.7M: 3 things to know
Supply chain tip of the day: Consider seasonal indexes when demand planning
Patient death spurs FDA to halt cancer drug trials
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
